AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Shares of AstraZeneca PLC AZN rallied 1.54% to £101.44 Wednesday, on what proved to be an all-around favorable trading ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

If you are looking for a deeply undervalued AI stock that is more promising than AZN but that trades at less than 5 times its ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...